Encelimab
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) [1].
Product Specifications
CAS Number
2173096-82-5
UNSPSC
12352203
Target
LAG-3
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/encelimab.html
Purity
95.25
Solubility
10 mM in DMSO
Smiles
[Encelimab]
Molecular Weight
(144.58 kDa)
References & Citations
[1]Perez-Santos M, et al. Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents. Expert Opin Drug Discov. 2022 Dec;17 (12) :1341-1355.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog